Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy
Roberto Bolli, Xian‐Liang Tang, Joshua M. Hare, Raul D. Mitrani et autres
us, it (code pays fourni par la source)